Bitektine Erica, Hagh-Daoust Hamila, Michel René P, Isnard Stephane, Routy Jean-Pierre
Department of Internal Medicine, McGill University, Montreal, Canada.
Department of Pathology, McGill University, Montreal, Canada.
Eur J Case Rep Intern Med. 2024 Nov 6;11(12):004908. doi: 10.12890/2024_004908. eCollection 2024.
Castleman disease (CD) is a rare lymphoproliferative disorder having a variegated clinical presentation. Diagnosis of the idiopathic HIV- and HHV8-negative multicentric CD (iMCD) subtype poses a challenge given its non-specific clinical manifestations. iMCD presents as diffuse lymphadenopathy with inflammatory manifestations, primarily driven by interleukin-6 (IL-6). Treatment includes suppressing the inflammation by targeting IL-6 with monoclonal antibodies such as siltuximab and, in severe cases, immuno-chemotherapy to control B- and plasma-cell activation.
A previously healthy 43-year-old male presented to the emergency department with fever, night sweats, anasarca, anaemia, thrombocytopenia and acute renal insufficiency. Extensive blood and imaging workup was initiated. Several diagnoses were entertained including viral infections (comprising COVID-19), haemophagocytic lymphohistiocytosis, lymphoma and autoimmune conditions. Initial axillary lymph node biopsy was not diagnostics. A positron emission tomography (PET) scan showed diffuse and symmetrical cervical and hilar/mediastinal lymphadenopathies. A mediastinal lymph node biopsy was then performed and indicated iMCD. The patient was treated with high-dose steroids and siltuximab. An Epstein-Barr virus (EBV) PCR was positive, and rituximab was added to the treatment. The patient recovered and felt well after two months.
Non-specific symptoms, non-diagnostic first biopsy and iMCD resemblance to haemophagocytic lymphohistiocytosis further complicated the diagnosis. A PET scan allowed the best selection of a lymph node to be biopsied. Anti-IL6 is the recommended treatment; however, we are lacking information on the duration of siltuximab, and the long-term toxicity and immunosuppressive effect of this treatment. The contribution of EBV reactivation in the development and treatment of iMCD needs further investigation.
A positron emission tomography (PET) scan is important to identify the optimal lymph node biopsy site for diagnostics.Epstein-Barr virus reactivation has a role in the pathogenesis and treatment choice of idiopathic multicentric Castleman disease.
卡斯特曼病(CD)是一种罕见的淋巴增殖性疾病,临床表现多样。鉴于其非特异性临床表现,特发性HIV和HHV8阴性多中心CD(iMCD)亚型的诊断具有挑战性。iMCD表现为伴有炎症表现的弥漫性淋巴结病,主要由白细胞介素-6(IL-6)驱动。治疗包括用单克隆抗体(如司妥昔单抗)靶向IL-6来抑制炎症,在严重情况下,采用免疫化疗来控制B细胞和浆细胞的激活。
一名43岁的既往健康男性因发热、盗汗、全身性水肿、贫血、血小板减少和急性肾功能不全就诊于急诊科。启动了广泛的血液和影像学检查。考虑了多种诊断,包括病毒感染(包括COVID-19)、噬血细胞性淋巴组织细胞增生症、淋巴瘤和自身免疫性疾病。最初的腋窝淋巴结活检未能明确诊断。正电子发射断层扫描(PET)显示颈部和肺门/纵隔弥漫性对称性淋巴结肿大。随后进行了纵隔淋巴结活检,结果提示为iMCD。该患者接受了大剂量类固醇和司妥昔单抗治疗。爱泼斯坦-巴尔病毒(EBV)聚合酶链反应(PCR)呈阳性,遂在治疗中加用了利妥昔单抗。患者在两个月后康复且感觉良好。
非特异性症状、初次活检未能明确诊断以及iMCD与噬血细胞性淋巴组织细胞增生症相似,使诊断进一步复杂化。PET扫描有助于最佳地选择活检的淋巴结。抗IL-6是推荐的治疗方法;然而,我们缺乏关于司妥昔单抗治疗持续时间以及该治疗的长期毒性和免疫抑制作用的信息。EBV再激活在iMCD发生发展及治疗中的作用需要进一步研究。
正电子发射断层扫描(PET)对于确定诊断所需的最佳淋巴结活检部位很重要。爱泼斯坦-巴尔病毒再激活在特发性多中心卡斯特曼病的发病机制和治疗选择中起作用。